Squamous Cell Papillomatosis in the Setting of Recurrent Respiratory Papillomatosis

被引:0
作者
Pasha L. Bentley
Michael J. Coulter
Brenda L. Nelson
机构
[1] Naval Medical Center San Diego,Department of Anatomic Pathology
[2] Naval Medical Center San Diego,Department of Otolaryngology
[3] Naval Medical Center San Diego,Department of Pathology
来源
Head and Neck Pathology | 2019年 / 13卷
关键词
Recurrent respiratory papillomatosis; Squamous cell papilloma; Squamous cell papillomatosis; HPV; Immunologic dysregulation; PDL-1; RRP;
D O I
暂无
中图分类号
学科分类号
摘要
A 23 year old male presented to the Otolaryngology clinic with 6 months of hoarseness and poor voice projection without improvement from speech therapy or medical anti-reflux medication. Upon examination he was found to have multiple polypoid lesions emanating from bilateral false vocal folds, left true vocal fold, and the anterior commissure. Biopsy and potassium titanyl phosphate (KTP) laser ablation with bevacizumab injection provided treatment and confirmed the clinical suspicion of squamous cell papilloma. Despite 3 years of treatment, the papillomatosis proved difficult to control, requiring a procedure approximately every 3 months. In an attempt to control the course of the disease the patient received a series of three bevacizumab and three cidofovir injections. Serial biopsies showed mild atypia within the squamous cell papillomas. Two separate biopsies confirmed presence of human papillomavirus (HPV) 6/11 via in situ hybridization with appropriate controls. There is promising research that the quadrivalent HPV (types 6, 11, 16, and 18) vaccine both reduces the disease burden in patients with active disease and reduces the incidence of recurrent respiratory papillomatosis (RRP). Other studies have shown that local immunologic dysregulation may play a role in RRP pathogenesis. Therefore new treatment options, to include PDL-1 blockade, offer hope in treating this benign condition with high morbidity and rare mortality.
引用
收藏
页码:235 / 238
页数:3
相关论文
共 117 条
  • [11] Loke SL(2006)Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 Vaccine 24 5571-106
  • [12] Larkin S(2017)Gardasil vaccination for recurrent laryngeal papillomatosis in adult men: first report: changes in HPV antibody titer J Voice 31 104-3236
  • [13] Wiatrak BJ(2016)Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis Eur Arch Otorhinolaryngol 273 3231-388
  • [14] Wiatrak DW(2015)Immune dysregulation in patients persistently infected with human papillomaviruses 6 and 11 J Clin Med 4 375-E32
  • [15] Broker TR(2018)The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis Laryngoscope 128 E27-138
  • [16] Lewis L(2017)PD-L1 expression and CD8 + infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis Int J Pediatr Otorhinolaryngol 95 133-undefined
  • [17] Ruiz R(undefined)undefined undefined undefined undefined-undefined
  • [18] Achlatis S(undefined)undefined undefined undefined undefined-undefined
  • [19] Verma A(undefined)undefined undefined undefined undefined-undefined
  • [20] Born H(undefined)undefined undefined undefined undefined-undefined